Results 61 to 70 of about 1,666,323 (310)

Rapid creation and quantitative monitoring of high coverage shRNA libraries. [PDF]

open access: yes, 2009
Short hairpin RNA libraries are limited by low efficacy of many shRNAs and by off-target effects, which give rise to false negatives and false positives, respectively. Here we present a strategy for rapidly creating expanded shRNA pools (approximately 30
Bassik, Michael C   +8 more
core   +2 more sources

RKIP overexpression reduces lung adenocarcinoma aggressiveness and sensitizes cells to EGFR‐targeted therapies

open access: yesMolecular Oncology, EarlyView.
RKIP, a metastasis suppressor protein, modulates key oncogenic pathways in lung adenocarcinoma. In silico analyses linked low RKIP expression to poor survival. Functional studies revealed RKIP overexpression reduces tumor aggressiveness and enhances sensitivity to EGFR‐targeted therapies, while its loss promotes resistance.
Ana Raquel‐Cunha   +10 more
wiley   +1 more source

Label-Free Immunosensor Based on Polyaniline-Loaded MXene and Gold-Decorated β-Cyclodextrin for Efficient Detection of Carcinoembryonic Antigen

open access: yesBiosensors, 2022
Multiple strategies have been employed to improve the performance of label-free immunosensors, among which building highly conductive interfaces and introducing suitable biocompatible carriers for immobilizing antibodies or antigens are believed to be ...
Qi Wang, Huaqian Xin, Zhou Wang
doaj   +1 more source

A bioinformatics screen identifies TCF19 as an aggressiveness‐sustaining gene in prostate cancer

open access: yesMolecular Oncology, EarlyView.
Gene expression meta‐analysis in multiple prostate cancer patient cohorts identifies Transcription factor 19 (TCF19) as an aggressiveness‐sustaining gene with prognostic potential. TCF19 is a gene repressed by androgen signaling that sustains core cancer‐related processes such as vascular permeability or tumor growth and metastasis.
Amaia Ercilla   +15 more
wiley   +1 more source

A blood-based transcriptomic signature stratifies severe Crohn’s disease and defines potentially targetable therapeutic pathways

open access: yesFrontiers in Gastroenterology, 2023
IntroductionDespite advances in medical therapy, many patients with Crohn’s disease (CD) ultimately require surgery for disease management. Identifying the underlying molecular pathways for subgroup stratification is critical to the improvement of ...
Rivkah Gonsky   +8 more
doaj   +1 more source

Immunocompetent murine models for the study of glioblastoma immunotherapy. [PDF]

open access: yes, 2014
Glioblastoma remains a lethal diagnosis with a 5-year survival rate of less than 10%. (NEJM 352:987-96, 2005) Although immunotherapy-based approaches are capable of inducing detectable immune responses against tumor-specific antigens, improvements in ...
Bloch, Orin   +9 more
core   +2 more sources

CD9‐association with PIP2 areas is regulated by a CD9 salt bridge

open access: yesFEBS Open Bio, EarlyView.
The tetraspanin CD9 has an intracellular salt bridge. If CD9 opens, open‐CD9 moves from PIP2‐rich areas to regions populated by its interaction partner EWI‐2. Hence, the state of the salt bridge regulates the distribution of CD9 and by this CD9‐EWI‐2 complex formation.
Yahya Homsi   +2 more
wiley   +1 more source

Epitopes identified in GAPDH from Clostridium difficile recognized as common antigens with potential autoimmunizing properties

open access: yesScientific Reports, 2018
Clostridium difficile (CD) infections are a growing threat due to the strain resistance to antibiotic treatment and the emergence of hypervirulent strains.
Agnieszka Razim   +9 more
doaj   +1 more source

Lymphoma versus Carcinoma and Other Collaborations

open access: yesCells, 2022
David Mason started his research career at a time when lymphoma diagnosis was based primarily on cellular morphology, clinical symptoms and special cytochemical stains using formalin fixed tissue sections.
Karen Pulford
doaj   +1 more source

Durable B‐Cell Impairment While Sparing IgA B Cells After Ocrelizumab Therapy in Multiple Sclerosis

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objectives Ocrelizumab (OCR), a humanized anti‐CD20 monoclonal antibody, is highly efficient in relapsing–remitting multiple sclerosis (RR‐MS). We assessed early cellular B‐cell profiles in patients prior to OCR treatment, on OCR treatment, and after 15 months of therapy discontinuation.
Alexandra Garcia   +20 more
wiley   +1 more source

Home - About - Disclaimer - Privacy